138 related articles for article (PubMed ID: 10803797)
1. The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: a double-blind, placebo-controlled study.
Snow BJ; Macdonald L; Mcauley D; Wallis W
Clin Neuropharmacol; 2000; 23(2):82-5. PubMed ID: 10803797
[TBL] [Abstract][Full Text] [Related]
2. Amantadine for dyskinesia in Parkinson's disease.
Crosby NJ; Deane KH; Clarke CE
Cochrane Database Syst Rev; 2003; 2003(2):CD003467. PubMed ID: 12804468
[TBL] [Abstract][Full Text] [Related]
3. Amantadine in Parkinson's disease.
Crosby N; Deane KH; Clarke CE
Cochrane Database Syst Rev; 2003; 2003(1):CD003468. PubMed ID: 12535476
[TBL] [Abstract][Full Text] [Related]
4. Amantadine's role in the treatment of levodopa-induced dyskinesia.
Rodnitzky RL; Narayanan NS
Neurology; 2014 Jan; 82(4):288-9. PubMed ID: 24371305
[No Abstract] [Full Text] [Related]
5. Buspirone and Zolmitriptan Combination for Dyskinesia: A Randomized, Controlled, Crossover Study.
LeWitt PA; Stebbins GT; Christensen KV; Tan R; Pretorius A; Thomsen M
Mov Disord; 2024 Mar; 39(3):613-618. PubMed ID: 38314643
[TBL] [Abstract][Full Text] [Related]
6. Amantadine use in the French prospective NS-Park cohort.
Fabbri M; Rousseau V; Corvol JC; Sommet A; Tubach F; De Rycke Y; Bertille N; Selvarasa Y; Carvalho S; Chaigneau V; Brefel-Courbon C; Ory-Magne F; Tessier S; Tir M; Bereau M; Meissner WG; Thiriez C; Marques A; Remy P; Schneider V; Moro E; Defebvre L; Houeto JL; Prange S; Eusebio A; Geny C; Frismand S; Damier P; Reuther CG; Castelnovo G; Benatru I; De Maindreville AD; Drapier S; Maltête D; Lagha-Boukbiza O; Rascol O;
J Neural Transm (Vienna); 2024 Jul; 131(7):799-811. PubMed ID: 38578434
[TBL] [Abstract][Full Text] [Related]
7. Motor complications in Parkinson's disease: 13-year follow-up of the CamPaIGN cohort.
Kim HJ; Mason S; Foltynie T; Winder-Rhodes S; Barker RA; Williams-Gray CH
Mov Disord; 2020 Jan; 35(1):185-190. PubMed ID: 31965629
[TBL] [Abstract][Full Text] [Related]
8. Influence of single nucleotide polymorphisms in COMT, MAO-A and BDNF genes on dyskinesias and levodopa use in Parkinson's disease.
Cheshire P; Bertram K; Ling H; O'Sullivan SS; Halliday G; McLean C; Bras J; Foltynie T; Storey E; Williams DR
Neurodegener Dis; 2014; 13(1):24-8. PubMed ID: 24008922
[TBL] [Abstract][Full Text] [Related]
9. CLINICAL TRIAL HIGHLIGHTS - DYSKINESIA.
McFarthing K; Prakash N; Simuni T
J Parkinsons Dis; 2019; 9(3):449-465. PubMed ID: 31356217
[No Abstract] [Full Text] [Related]
10. Amantadine for Refractory Tremor in Parkinson Disease and Other Indications: A Chart Review With Long-Term Follow-up.
Friedman JH
Clin Neuropharmacol; 2023 Sep-Oct 01; 46(5):169-170. PubMed ID: 37747997
[TBL] [Abstract][Full Text] [Related]
11. Moving chin left and right: levodopa induced dyskinesia in spinocerebellar ataxia type 3?
Cao L; Zheng Z; Zhao G
Acta Neurol Belg; 2023 Dec; 123(6):2371-2373. PubMed ID: 36696007
[No Abstract] [Full Text] [Related]
12. Levodopa-induced dyskinesia: do current clinical trials hold hope for future treatment?
Alsalmi M; Al-Kassmy J; Kang W; Palayew M; Huot P
Expert Opin Pharmacother; 2024; 25(1):1-3. PubMed ID: 38116733
[No Abstract] [Full Text] [Related]
13. Neuroplasticity in levodopa-induced dyskinesias: An overview on pathophysiology and therapeutic targets.
Bove F; Angeloni B; Sanginario P; Rossini PM; Calabresi P; Di Iorio R
Prog Neurobiol; 2024 Jan; 232():102548. PubMed ID: 38040324
[TBL] [Abstract][Full Text] [Related]
14. Levodopa Impairs the Energy Metabolism of the Basal Ganglia In Vivo.
Prasuhn J; Schiefen T; Güber T; Henkel J; Uter J; Steinhardt J; Wilms B; Brüggemann N
Ann Neurol; 2024 May; 95(5):849-857. PubMed ID: 38366778
[TBL] [Abstract][Full Text] [Related]
15. Ropinirole monotherapy induced severe reversible dyskinesias in Parkinson's disease.
Batla A; Stamelou M; Mencacci N; Schapira AH; Bhatia KP
Mov Disord; 2013 Jul; 28(8):1159-60. PubMed ID: 23386566
[No Abstract] [Full Text] [Related]
16. Extended-release amantadine for OFF-related dystonia in Parkinson's disease.
Espay AJ; Ostrem JL; Formella AE; Tanner CM
Parkinsonism Relat Disord; 2024 May; 122():106088. PubMed ID: 38461688
[TBL] [Abstract][Full Text] [Related]
17. Amantadine toxicity causing visual hallucinations.
Barbara JM; Pace A
Pract Neurol; 2023 Oct; 23(5):418-419. PubMed ID: 37419676
[TBL] [Abstract][Full Text] [Related]
18. Amantadine-induced livedo racemosa.
Chakraborty U; Banerjee S; Chandra A; Sil A
BMJ Case Rep; 2024 Jan; 17(1):. PubMed ID: 38216170
[No Abstract] [Full Text] [Related]
19. Relapse of Tardive Dyskinesia Following Successful Treatment With Amantadine: A Case Report.
Kusudo K; Uchida H; Okada Y; Yoshida K
J Clin Psychopharmacol; 2024 Jul-Aug 01; 44(4):424-425. PubMed ID: 38497680
[No Abstract] [Full Text] [Related]
20. Amantadine Responsive Methcathinone (Ephedrone) Induced Parkinsonism.
Thaler A; Gurevich T
Mov Disord Clin Pract; 2024 Apr; 11(4):429-430. PubMed ID: 38168101
[No Abstract] [Full Text] [Related]
[Next] [New Search]
